Generali Investments Management’s Colgate-Palmolive CL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.33M Buy
25,401
+4,736
+23% +$414K 0.51% 47
2026
Q1
$1.76M Sell
20,665
-5,760
-22% -$513K 0.41% 54
2025
Q4
$2.09M Buy
26,425
+23,458
+791% +$1.84M 0.42% 51
2025
Q3
$237K Sell
2,967
-11,394
-79% -$972K 0.05% 133
2025
Q2
$1.3M Sell
14,361
-2,480
-15% -$226K 0.3% 75
2025
Q1
$1.58M Buy
16,841
+1,746
+12% +$156K 0.45% 59
2024
Q4
$1.37M Buy
+15,095
New +$1.44M 0.35% 63

Other funds holding CL

Generali Investments Management's CL Position: Q2 2026 in Review

Generali Investments Management increased its Colgate-Palmolive (CL) stake by 23% in Q2 2026, buying an estimated $414K and bringing the position to 25,401 shares worth $2.33M. The position accounts for 0.51% of the portfolio, ranked #47.

Generali Investments Management first reported a position in CL in Q4 2024 and has held it in 7 quarters since. 597 funds tracked by Wall St. Rank hold CL as of Q2 2026.

  • Generali Investments Management held 25,401 shares of Colgate-Palmolive worth $2.33M as of Q2 2026.
  • Generali Investments Management bought 4,736 Colgate-Palmolive shares in Q2 2026, an estimated $414K.
  • Colgate-Palmolive made up 0.51% of Generali Investments Management's portfolio in Q2 2026, its #47 holding.
  • Generali Investments Management first reported a position in Colgate-Palmolive in Q4 2024 and has held it in 7 quarters since.
  • 597 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q2 2026.

Based on Generali Investments Management's 13F filing for Q2 2026, filed 10 Jul 2026.